ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting.

  • Double Hematopoietic Cell Transplantation Extends Progression-Free Survival Over Single Transplant in Myeloma Patients Thursday, February 2nd, 2017 | February 2017, Volume 3, Issue 3

    Following bortezomib-based induction therapy, patients with newly diagnosed multiple myeloma (MM) who received double autologous hematopoietic cell transplantation (AHCT) had longer progression-free survival (PFS) than patients who received a single AHCT, according to preliminary results from a phase III study by the European Myeloma Network. The benefit appeared to be greatest for patients who had […]

  • Does the Addition of ATLG Improve Outcomes After Allogeneic Transplantation? Thursday, February 2nd, 2017 | February 2017, Volume 3, Issue 3

    Previous studies have suggested that adding anti-T lymphocyte globulin (ATLG) to the treatment regimen for patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) could reduce the incidence of acute and chronic graft-versus-host disease (aGVHD; cGVHD), but a randomized, double-blind, phase III trial presented at the 2016 ASH Annual Meeting showed mixed results. After two years of […]

  • For Patients on Dialysis With Venous Thromboembolism, Low-Molecular-Weight Heparin May Be a Better Option Than Vitamin K Antagonist Thursday, February 2nd, 2017 | February 2017, Volume 3, Issue 3

    Low-molecular-weight heparins (LMWHs) are not traditionally used to treat venous thromboembolism (VTE) in patients on dialysis, but results from a study presented at the 2016 ASH Annual Meeting suggest that the agents do not increase major bleeding risk compared with vitamin K antagonist (VKA) monotherapy – the traditional treatment in this setting. To compare the […]

  • Balancing Bleeding and Thrombosis Risk With Anticoagulation in Patients With Hematologic Malignancies and Thrombocytopenia Tuesday, January 17th, 2017 | January Annual Meeting Edition 2017, Volume 3, Issue 2

    Two studies presented at the 2016 ASH Annual Meeting examined the safety of anticoagulation therapy in patients with hematologic malignancies – a population with an increased risk of venous thromboembolism (VTE), despite periods of thrombocytopenia in subsets. While the first study supports the safety of anticoagulation, the second study questions the use of a “standard” […]

  • Results from Phase III SWOG Trial: 7+3 Still the Standard of Care for Patients With Acute Myeloid Leukemia Tuesday, January 17th, 2017 | January Annual Meeting Edition 2017, Volume 3, Issue 2

    Remission induction with 7+3 chemotherapy (cytarabine + daunorubicin) should remain the standard of care for younger patients with acute myeloid leukemia (AML), according to results from the phase III SWOG S1203 trial, which evaluated whether adding the histone deacetylase (HDAC) inhibitor vorinostat to a regimen of idarubicin and high-dose cytarabine, or whether idarubicin and high-dose […]

1 of 16
back to top